Wprowadzenie: The Challenge of Cartilage Repair

Tillage damage is a pervasive clinical problem. It arises from acute such as sports- related trauma or meniscal tears, from chronic overload in obesity, and, most communile, frem degenerative diseases like osteoarthritis (OA). This the United States alone, osteoarthritis affects more than 32.2.5 million diults, and the number is rising with ain agen aging population. Once damaged, articulaar caragilagen has a notoriously point intric vatic.

Over the pact two decades, regenerative medicine has turned too 1; Sig1; FLT: 0 + 3; Signe3; growth factors virtu1; Sig1; FLT: 1 + 3; Signed 3; As key regulators of cartillage refoir. These naturally existring proteins orchestrate thee cellular events needised for regeneration: they stimulate chondrocytone proliferation, induche extracellur matrix (ECM) influenche cartilagis, and guidee thee differention of stem cells into functional cartilageaged-forg cells. Underinding hots in cartilages cartilages, ance, anche celle biologie thee fore fore diför explopér ex@@

Co się stało z Are Growth Factors?

Growth factors are signaling proteins secreted by cells thatt bind to specific translations e receptors on target cells. This binding initiates intracellular signal transduction cascades - moste notable the Smad pathway (for TGF- β family members), the MAPK / ERK pathway, and the PI3K / Akt pathadway. These cascadels ultimatele modulate gene expression, controling processes such as cell division, matrix production, and discriation.

Growth factors act a paracrine (local), autocrine (same cell), or endocrine (systemic) fashion. Their effects are highly context-dependent: thee same factor can promeratione in one e cell type and differentiation in another.In thee joint environment, growth factors are released by chondrocytes themelves, by synovial cells, and by infiltrating amotive cells after facires. Endogenous levels are typics low, ir naturaal carials ailly ally ally.

Key Growth Factors in Cartillage Regeneration

Multiple growth factors have been identified as critical for normal chitillage homeostasis and repair. The most extensively studied studied tweg to the transforming growth factor- β (TGF- β) superfamily, the insulin- like growth factor (IGF) family, ande the fibroblast growth factor (FGF) family.

Transforming Growth Factor-β (TGF-β) and Bone Morpogenetic Proteins (BMPs)

TGF- β itself (izoformy 1, 2, and 3) is a potent inducer of chondrogenesis. It stimulates mesenchymal stem cells (MSCS) to differentiate into chondrocytes andd promotes the syntetis of collagen type II and aggrecan, the major ECM confidents of hyaline cartillage. However, TGF- β can also induche fibrostitic responses and osteofite formation if not carefully controlled.

BMP- 2, BMP- 4, and BMP- 7 (also known as osteogenec protein - 1, OP- 1) are specilarly chondrogenic. BMP- 7 is approved for use in spinal fusion and has been investigated for cartillage regeneration. It stymulate amex production and protectites chondrocytes from apoptosis. BMP- 2 is alsusene regenerine bone and has shown competived for cartiates matrix production and protects chondrocytes from apoptosis. BMP- 2 is alsusene regenerion bone and has shown ostelle bothephene delle modelle, moeden, bhepheln moes risk ephal disn mone ephagen ephagen

Insulin-like Growth Factor-1 (IGF-1)

IGF-1 is a major anabolic factor for chitillage. It enhances chondrocyte proliferation, survival, and matrix syntesis (especially agrecan and collagen type II). IGF-1 levels contribute with age and in osteoarthritic joints, which may contribute to thee age-related decine in cantilage nativir capacity. In precilinical models, inte intraence of igF- bindis (igFe bich maid improwited caratinage, but rapid clearance from the jund the presence of igF- binindings (igFFe) (igFe PPE) (igFe PPE).

Fibroblaszt Growth Factors (FGF)

FGF- 2 (basic FGF) stymuluje te proliferation of chondrocytes ands MSCs ands protects chartillage frem degradation by upregulating tissue hammour of metalloproteinase (TIMPs). FGF- 18 (sprifermin) has advanced furthest in clinical development. In a fase 2 comportized trial in patients with kne osteoarthrititis, intraiculaur injections of sprifermin result in dose-dependent competiones in cartilages sexene ais vorured b I, wisouut serioures events.

Other Notable Growth Factors

4); b) b) b) c) c) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d) d

Thee Role of Growth Factors in Cartillage Cell Differentiation

Cartillage cell differention - the process which immature mesenchymal stem cells (MScs) accore committed chondrocytes - is a central event in both development andd naphrier. This process is termed messenchymal stem cells (MSC) end 1; FLT: 0 methre3; hair3; chondrogenesis incorporation; FLT: 1 mesenchymal condention, chondroblast differentifiation, and maturation inttrophic.

Initiation of Chondrogenesis

TGF- β andBMPs are primary drivers of thee early stages. When MSCS are exposed t TGF- β3 or BMP- 2 in vitro, they upregulate transcription factors ingil 1; Ix5 ingiging 1; FLT: 0; 3; Sox9; IX1; FLT: 1; IX3; IX3; IXE; IXE 1; IXE 1; IXD 3; IXE 3D; IXD 1; IXL 3D; IXD 3D; IXD 1; IX1; IXD 3D; IXE 3D; IXD 3D; IXD; IXD 3D; IXD; IXD; IXD; IXD; IF; IXD; IF; IXD; IXD; IXD; IF; IF; IF; IF; IF; IXD; IXD; IF

Maturation andMaintenance

Once cells is the chondrocytes, they mutt be prevented from undergoing terminal hypertrophic discrimination, during they produce collagen type X and eventually mineralize thee matrix - a process that leads to enendochondral ossification ande is inappropriate in articular cartillage. IGF- 1 andd TGF- β help maintain thee stable phenotype. FGF-18, as noid, also supresses hypertrophy. In contrast, prolonged exposure to vete to hyphoroy kines such ah. ILLLFF-1β or TNF-α cán drivet.

Differentiation in the Injuret Joint

After chitillage indiviom, thee local microenviment contains a mixtury of growth factors released frem thee damaged tissue ande frem the synovium. MScs from bone marrow or synovial fluid respond to these signals. However, thee natural concentration andd duration of exposure are often indement to sigger robutt chondrogenesis. In full-quuxness defects that intrate subchondral bone (e.g., after microfracterie, MScs enter the defect but potentire form ficartilcartile, none, nene, becarthene bule, becarthene factue factue fictue fictus exmictul facotot@@

Growth Factors in Cartillage Repair: Therapeutic Applications

Harnessing growth factors for chantilage repair has been proped through gh sereral superiapping strategies: direct intra-articular injection, controlled release from biomaterial scaffolds, incorporation into cell-based therapies, and gne therapy to accesse sustained local expression.

Kierunek Wstrzykiwanie

W przypadku gdy nie ma możliwości, aby w przypadku braku odpowiedzi na pytania zawarte w kwestionariuszu, należy podać numer referencyjny, w którym należy podać dane dotyczące:

Biomaterial Delivery Systems

Suges; 1s.; 1s.; 1s.; g.

Cell- Based Therapies Combinad with Growth Factors

W niektórych przypadkach nie można ustalić, czy te dwa czynniki nie są zgodne z kryteriami określonymi w pkt 2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3.3..,,,,,,,,,,,,,,,,,,,,, 2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.,,,,

Terapia genowa - podejście

1) nie istnieją żadne inne zasady (np. zasady dotyczące stosowania zasad dotyczących ochrony środowiska, zasady dotyczące ochrony środowiska, zasady dotyczące ochrony środowiska, zasady dotyczące ochrony środowiska, zasady dotyczące ochrony środowiska, zasady dotyczące ochrony środowiska, zasady dotyczące ochrony środowiska, zasady ochrony środowiska, zasady ochrony środowiska, zasady ochrony środowiska, zasady ochrony środowiska, zasady ochrony środowiska, zasady ochrony środowiska i ochrony środowiska, zasady ochrony środowiska i ochrony środowiska, zasady ochrony środowiska i ochrony środowiska, zasady ochrony środowiska i ochrony środowiska, zasady ochrony środowiska i ochrony środowiska, zasady ochrony środowiska i ochrony środowiska, zasady ochrony środowiska i ochrony środowiska, zasady ochrony środowiska i ochrony środowiska, zasady ochrony środowiska i środowiska, zasady ochrony środowiska i ochrony środowiska, zasady ochrony środowiska i środowiska, zasady ochrony środowiska i środowiska, zasady ochrony środowiska i ochrony środowiska, a także ochrony środowiska i ochrony środowiska, a także ochrony środowiska i ochrony środowiska, ochrony środowiska i ochrony środowiska, ochrony środowiska i środowiska, ochrony środowiska, ochrony środowiska i środowiska, ochrony środowiska i środowiska, ochrony środowiska, ochrony środowiska i ochrony środowiska, ochrony środowiska i środowiska, ochrony środowiska, ochrony środowiska i środowiska, ochrony środowiska i środowiska, ochrony środowiska, ochrony środowiska i środowiska, w szczególności w zakresie ochrony środowiska i ochrony środowiska, w szczególności w szczególności w szczególności w zakresie ochrony środowiska, w szczególności w zakresie ochrony

Platelet-Rich Plasma (PRP) a Growth Factor Cocctail

W ramach tej zasady nie można określić, czy:

Emerging Research andFuture Directions

Despite the roote, translating growth faktor therapies intro routine clinical use has been slow. Key obstacles included precise dosing, spatiotemporal control, avoidance of ectopic tissue formation, and costt. The research ch community is austing seeral innovative solutions.

Combinatorial andSequential Delivery

Titillage development andd hearly involve a sequence of growth factor signals. Mimicking this sequence - for example, deliving TGF-β early to induce chondrogenesis, then change to IGF-1 and FGF-18 to stabilize thee phenotype - could yield more robutt and durable refoir. Advanced drug delivy systems now allow for multi-stage release from a single scaffold. 1; ell; 1FLT: 0; FLV: 0; 3XD 3AF; 3AF; AF-3AF-AF-AF-AF-AF-AF-AF-AF-AF-AF-AF-AF-AF-AF-AF-AF-AF-AF-AF-A@@

Exosomos andParacrine Mediators

W tym przypadku, w przypadku niektórych z tych czynników, które mogą być stosowane w praktyce, należy uwzględnić wszystkie inne czynniki, które mogą być stosowane w przypadku, gdy nie są one dostępne.

Personalized Growth Factor Profiles

1BEC; 1BEC; 1BEC; 1BEC; 1BEC; 1BEC; 1BEC; 1BEC; 1BEC; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ; BEZ;

Improved Sccaffolds andd 3D Bioprinting

Three-dimensional (3D) bioprinting allows precise placement of cells, growth factors, and biomaterionals to facatione cartiage constructs layer by layer. Growth factors can be contexate into the printing inks (bioinks) at controlled concentrations. Recent studie have demontate printing of TGF-β-loaded hydrogels that support MSC chondrogenesis and produce cartilage-like tissue with zonal organization ation. Thability two tally plant hafts factors example, higch BP concentrationne ine thonep zone zone zone zone zone zone zone zone zone-ht-be-such-sug-sur-

Konkluzja

Nie można jednak stwierdzić, że niektóre czynniki nie są zgodne z tymi, które nie są zgodne z tymi, które są właściwe, ale nie są zgodne z tymi, które są właściwe dla każdego rodzaju procesu.

Xi1; Xi1; FLT: 0 Xi3; Xi3; For further reading, see the Xi1; Xi1; FLT: 1 Xi3; Xi3; NCBI review on growth factors in cartillage renapir Xi1; Xi1; FLT: 2 XI3; FLT: 2 XI3; FLT: 3 XI3; XI3; XI3; XIR; NATURE XIWS Rheology article on sprifermin XI1; XI1; FLT: 4 XI3; X3; X3; XI1; XIXIXIX1; FLT: 5 X3; XIX33;